| Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008) T Wahlgren, U Harmenberg, P Sandström, S Lundstam, J Kowalski, ... British journal of cancer 108 (7), 1541-1549, 2013 | 118 | 2013 |
| The survival of new products M Asplund, R Sandin Review of Industrial Organization 15, 219-237, 1999 | 86 | 1999 |
| Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2 AV Soerensen, F Donskov, GG Hermann, NV Jensen, A Petersen, ... European Journal of Cancer 50 (3), 553-562, 2014 | 81 | 2014 |
| Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation L Jönsson, R Sandin, M Ekman, J Ramsberg, C Charbonneau, X Huang, ... Value in Health 17 (6), 707-713, 2014 | 79 | 2014 |
| The number of firms and production capacity in relation to market size M Asplund, R Sandin The Journal of Industrial Economics 47 (1), 69-85, 1999 | 70 | 1999 |
| Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology B Sherrill, JA Kaye, R Sandin, JC Cappelleri, C Chen OncoTargets and therapy, 287-296, 2012 | 67 | 2012 |
| Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma Á Benedict, RA Figlin, P Sandström, U Harmenberg, A Ullén, ... BJU international 108 (5), 665-672, 2011 | 59 | 2011 |
| Methods for adjusting for bias due to crossover in oncology trials KJ Ishak, I Proskorovsky, B Korytowsky, R Sandin, S Faivre, J Valle Pharmacoeconomics 32, 533-546, 2014 | 58 | 2014 |
| Competition in interrelated markets: An empirical study M Asplund, R Sandin International Journal of Industrial Organization 17 (3), 353-369, 1999 | 40 | 1999 |
| Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma D Cella, MP Davis, S Négrier, RA Figlin, MD Michaelson, AG Bushmakin, ... Cancer 120 (12), 1871-1880, 2014 | 23 | 2014 |
| Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma S Négrier, AG Bushmakin, JC Cappelleri, B Korytowsky, R Sandin, ... European Journal of Cancer 50 (10), 1766-1771, 2014 | 19 | 2014 |
| The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden K Bolin, R Sandin, M Koltowska-Häggström, J Loftus, C Prütz, B Jonsson Cost Effectiveness and Resource Allocation 11, 1-9, 2013 | 17 | 2013 |
| Subsidies in oligopoly markets: a welfare comparison between symmetric and asymmetric costs SF Hamilton, R Sandin Public finance review 25 (6), 660-668, 1997 | 10 | 1997 |
Xin HuangAmgen Inc.Verified email at umassmed.edu
Xin HuangAmgen Inc.Verified email at umassmed.edu